Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma
Neoadjuvant immunotherapy significantly improves 5-year relapse-free survival in stage IIIB or greater melanoma patients, with major pathological response (MPR) showing the highest benefit. Neoadjuvant ICI therapies yield the highest MPR rates and 3-year event-free survival, outperforming BRAF/MEK targeted therapies. Patients achieving MPR have a 3-year relapse-free survival above 85%, while those without it only 40%. Overall survival is over 80% for all treatment groups, with MPR patients achieving 97-100% 3-year OS compared to 70% for non-response patients.
Reference News
Neoadjuvant immunotherapy significantly improves 5-year relapse-free survival in stage IIIB or greater melanoma patients, with major pathological response (MPR) showing the highest benefit. Neoadjuvant ICI therapies yield the highest MPR rates and 3-year event-free survival, outperforming BRAF/MEK targeted therapies. Patients achieving MPR have a 3-year relapse-free survival above 85%, while those without it only 40%. Overall survival is over 80% for all treatment groups, with MPR patients achieving 97-100% 3-year OS compared to 70% for non-response patients.